Display options
Cite
Rabatin A, Snider MJ, Boyd JM, et al. Safety of Twice Daily Sotalol in Patients with Renal Impairment: A Single Center, Retrospective Review. J Atr Fibrillation. 2018;11(3):2047doi: 10.4022/jafib.2047.
Rabatin, A., Snider, M. J., Boyd, J. M., Houmsse, M., & Boyd, J. M. (2018). Safety of Twice Daily Sotalol in Patients with Renal Impairment: A Single Center, Retrospective Review. Journal of atrial fibrillation, 11(3), 2047. https://doi.org/10.4022/jafib.2047
Rabatin, Abigail, et al. "Safety of Twice Daily Sotalol in Patients with Renal Impairment: A Single Center, Retrospective Review." Journal of atrial fibrillation vol. 11,3 (2018): 2047. doi: https://doi.org/10.4022/jafib.2047
Rabatin A, Snider MJ, Boyd JM, Houmsse M, Boyd JM. Safety of Twice Daily Sotalol in Patients with Renal Impairment: A Single Center, Retrospective Review. J Atr Fibrillation. 2018 Oct 31;11(3):2047. doi: 10.4022/jafib.2047. eCollection 2018. PMID: 31139270; PMCID: PMC6533816.
Copy Download .nbib Format: NLM
Share it on

J Atr Fibrillation. 2018 Oct 31;11(3):2047. doi: 10.4022/jafib.2047. eCollection 2018.

Safety of Twice Daily Sotalol in Patients with Renal Impairment: A Single Center, Retrospective Review.

Journal of atrial fibrillation

Abigail Rabatin, Melissa J Snider, J Michael Boyd, Mahmoud Houmsse, J Michael Boyd

Affiliations

  1. The Ohio State University Wexner Medical Center 452 West 10th Ave Columbus, OH 43210.

PMID: 31139270 PMCID: PMC6533816 DOI: 10.4022/jafib.2047

Abstract

BACKGROUND: The class III antiarrhythmic sotalol is renally eliminated with a dose-related propensity to cause adverse drug reactions (ADR) potentially leading to life-threatening arrhythmias. Although product labeling recommends once daily dosing in patients with renal impairment, twice daily dosing is commonly utilized. This study evaluates the safety of this practice.

METHODS: This retrospective, observational study examined renally impaired patients with atrial fibrillation or atrial flutter admitted for sotalol initiation from July 1, 2012 - December 31, 2014, then for up to 20 months after initiation. Primary endpoints included rates of ADR and therapy changes due to ADR. Secondary endpoints included therapy changes due to arrhythmia recurrence, admissions due to arrhythmia recurrence, and therapy changes for any cause.

RESULTS: Analysis included 134 patients with an average creatinine clearance of 51 ml/min, followed over a median of 170 days. Length of stay averaged 3 days withADR occurring in 53.7% of patients, most commonly QT prolongation or bradycardia. Therapy change due to ADR occurred in 45.5% of patients (n=61). Therapy change due to arrhythmia recurrence occurred in 23.1% (n=31), admission due to arrhythmia recurrence occurred in 24.6% (n=33), and therapy change for any cause occurred in 74.6% (n=100).

CONCLUSION: Initiating sotalol twice daily in renally impaired patients results in ADR and therapy change rates consistent with rates seen in clinical practice for non-renally impaired patients, with minimal length of stay.This practice may be reasonable when initiated in the acute care setting with subsequent outpatient monitoring, however further study is needed.

Keywords: Atrial Fibrillation; Dosing; Renal Dysfunction; Renal Impairment; Sotalol

References

  1. Am J Cardiol. 1999 Aug 1;84(3):270-7 - PubMed
  2. J Cardiovasc Pharmacol Ther. 2001 Apr;6(2):111-9 - PubMed
  3. N Engl J Med. 2005 May 5;352(18):1861-72 - PubMed
  4. Ann Pharmacother. 2009 May;43(5):840-8 - PubMed
  5. Clin Ther. 2009 Jun;31(6):1209-18 - PubMed
  6. Circulation. 2015 Jan 27;131(4):e29-322 - PubMed
  7. Pacing Clin Electrophysiol. 2015 Apr;38(4):490-8 - PubMed
  8. J Cardiol. 2016 May;67(5):471-6 - PubMed
  9. Ann Intern Med. 1997 Aug 15;127(4):281-4 - PubMed
  10. Am J Cardiol. 1997 Oct 23;80(8A):90G-98G - PubMed
  11. J Am Coll Cardiol. 1998 Jul;32(1):169-76 - PubMed

Publication Types